A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Mise à jour : Il y a 4 ans
Référence : NCT00541658

Femme Homme

Extrait

The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.


Critère d'inclusion

  • Postmenopausal osteoporosis


Liens